Introduction
============

Hepatocellular carcinoma (HCC) is one of the most common malignancies globally and the second-leading cause of mortality in China ([@b1-ol-0-0-8271]). There are \~62 million newly diagnosed cases of HCC annually worldwide ([@b2-ol-0-0-8271]). Numerous factors, including hepatitis B virus infection and alfatoxin induction, may contribute to the development of HCC. These factors may lead to abnormal gene expression, resulting in increased cancer cell proliferation and escape from immune surveillance ([@b3-ol-0-0-8271]--[@b5-ol-0-0-8271]). The majority of patients with HCC are diagnosed at advanced stages of the disease. Currently, there is no effective surgical or pharmaceutical treatment for HCC. Therefore, investigation of the molecular mechanisms underlying HCC development is necessary to develop therapeutic strategies for HCC.

With the development of sequencing technology and the in-depth studies of oncological diseases in previous years, long non-coding RNAs (lncRNAs), once considered to be the 'noise' in genomic transcription, have come to the attention of scholars ([@b6-ol-0-0-8271]--[@b8-ol-0-0-8271]). lncRNAs are non-protein-coding transcripts that are \>200 nucleotides, which may interact with various biomolecules, including DNA, RNA and proteins, to regulate gene expression at transcriptional, post-transcriptional and epigenetic levels ([@b9-ol-0-0-8271]), serving important functions in a wide range of biological processes, including cell proliferation, survival, differentiation and chromatin remodeling ([@b10-ol-0-0-8271],[@b11-ol-0-0-8271]). To date, the encyclopedia of DNA elements project (GENCODE v26) has conservatively annotated in humans close to 16,000 lncRNA genes that give rise to \>28,000 distinct transcripts ([@b12-ol-0-0-8271]). In previous years, researchers have made notable advances in the study of lncRNA and diseases, particularly in the area of tumors ([@b13-ol-0-0-8271]--[@b15-ol-0-0-8271]). It has been suggested that the abnormal expression of lncRNA may be the major inducer and accelerant of tumorigenesis ([@b16-ol-0-0-8271]). However, the functions of lncRNA and their underlying molecular mechanisms are not well understood, meaning that further studies are required.

Increasingly, evidence demonstrates that a number of abnormally expressed lncRNAs are closely associated with the occurrence, invasion, metastasis and recurrence of HCC, and have great potential in its prediction, diagnosis and treatment ([@b17-ol-0-0-8271]). The regulatory mechanism of lncRNA is complex, and its role in HCC is diverse ([@b18-ol-0-0-8271],[@b19-ol-0-0-8271]). The present study utilized bioinformatic analysis to investigate the regulatory network of HCC-associated lncRNAs and their target genes in order further understanding on the functions of lncRNA in the pathogenesis of HCC, which is also conducive to follow-up studies.

Materials and methods
=====================

### Identification of HCC-associated lncRNAs

The lncRNA disease database (<http://www.cuilab.cn/lncrnadisease>) has identified \>200 types of lncRNA-associated diseases and can be utilized as a bioinformatic tool to predict human lncRNA-associated diseases ([@b20-ol-0-0-8271]). In the present study, HCC-associated lncRNAs were screened and candidates lncRNAs were selected using the lncRNA disease database.

### lncRNA-miRNA interaction analysis

The interaction between miRNAs (6--8mer sites) and lncRNAs was predicted from the crosslinking immunoprecipitation RNA sequencing (CLIP-Seq) data using the starBase platform (<http://starbase.sysu.edu.cn/>) ([@b21-ol-0-0-8271]).

### Identification of HCC-associated miRNAs

HCC-associated miRNAs were mapped into the HMDD database (<http://202.38.126.151/hmdd/mirna/md/>) ([@b22-ol-0-0-8271]).

### Target gene prediction

ChIPBase (<http://deepbase.sysu.edu.cn/chipbase/>) is a database for decoding the transcriptional regulation of lncRNAs and miRNAs ([@b23-ol-0-0-8271]). The candidate transcription factors for lncRNAs and miRNAs were predicted using ChIPBase and analyzed using PubMed (<http://www.ncbi.nlm.nih.gov/pubmed/>).

### Identification of the target genes for the candidate miRNAs

miRWalk (<http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/>) is a comprehensive atlas of microRNA-target interactions, which provides the possible miRNA binding sites within the complete sequence of a gene ([@b24-ol-0-0-8271]). The target genes for the candidate miRNAs were identified using the miRWalk database.

### Identification of the HCC-associated target genes

OncoDB.HCC (<http://oncodb.hcc.ibms.sinica.edu.tw/index.htm>) is the first integrated oncogenomic database of hepatocellular carcinoma, which may aid identification aberrant cancer target genes and loci ([@b25-ol-0-0-8271]). Target genes that were not HCC-associated were further screened using the OncoDB.HCC database.

### Functional enrichment analysis

DAVID (<https://david.ncifcrf.gov/home.jsp>) is a database that provides functional interpretation of a large list of genes derived from genomic studies. DAVID accelerates the analysis of genome-scale datasets by facilitating the transition from data collection to biological meaning ([@b26-ol-0-0-8271]). In the present study, miRNA target genes were further analyzed using DAVID, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and it was considered to be significant if the Benjamini-corrected P-value was \<0.05.

### Identification of transcription factors for the target lncRNAs and miRNAs

ConSite is a web-based tool for identifying *cis*-regulatory elements in genomic sequences (<http://consite.genereg.net>). Predictions are made based on the integration of binding site prediction generated with high-quality transcription factor models and cross-species comparison filtering ([@b27-ol-0-0-8271]). The transcription factors for each target gene were predicted using ConSite. The transcription factors that were associated with HCC were further screened using PubMed.

### Construction of the regulatory network of lncRNAs in HCC

On the basis of the genomic information that was collected, the possible regulatory network of the selected lcnRNAs in HCC was constructed by Cytoscape software version 3.5.0 (<http://www.cytoscape.org/index.html>).

Results
=======

### HCC-associated lncRNAs

Of the 12 lncRNAs that were associated with HCC obtained from the lncRNA disease database ([Table I](#tI-ol-0-0-8271){ref-type="table"}), HOX antisense intergenic RNA (HOTAIR), metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and highly upregulated in liver cancer (HULC) were selected for further analysis.

### Analyses of the target lncRNAs

The three target lncRNAs, HOTAIR, MALAT1 and HULC, were analyzed using UCSC Genome Browser. As presented in [Fig. 1A](#f1-ol-0-0-8271){ref-type="fig"}, HOTAIR, MALAT1 and HULC were located on chromosome 12, 11 and 6, respectively. Additionally, MALAT1 and HULC were highly expressed in the liver, whereas HOTAIR was expressed in the liver at a lower level ([Fig. 1B](#f1-ol-0-0-8271){ref-type="fig"}).

### Prediction of the interaction between target lncRNAs and miRNAs

The miRNAs that were associated with HOTAIR, MALAT1 and HULC, were predicted using starBase2.0. A total of 32 miRNAs were predicted to interact with HOTAIR, and 113 miRNAs were predicted to interact with MALAT1. Among these miRNAs, miR-206, miR-1, miR-17-5p, miR-20a-5p, miR-93-5p, miR-106a-5p, miR-106b-5p, miR-613, miR-519d-5p, miR-217 and miR-20b-5p were overlapping ([Fig. 2](#f2-ol-0-0-8271){ref-type="fig"}). However, no miRNA was identified to interact with HULC. Therefore, HULC was excluded from further analysis.

### Identification of HCC-associated miRNAs

The HCC-associated miRNAs were obtained from HMDD and compared with the previously identified miRNAs. As presented in [Fig. 3](#f3-ol-0-0-8271){ref-type="fig"}, miR-1, miR-17-5p, miR-20a-5p, miR-93-5p, miR-106a-5p, miR-106b-5p, miR-519d-5p, miR-217 and miR-20b-5p were involved in the progression of HCC and were identified to interact with HOTAIR and MALAT1. A previous study demonstrated the negative association between miRNA and lncRNA ([@b28-ol-0-0-8271]). Therefore, in the present study, miR-1 and miR-20a-5p were selected for further analysis, owing to their low expression in HCC.

### Prediction of the regulatory association between transcription factors and target lncRNAs/miRNAs

The transcription factors for lncRNAs (MALAT1 and HOTAIR) and miRNAs (hsa-miR-1 and hsa-miR-20a-5p) were separately predicted using ChIPBase. As presented in [Fig. 4](#f4-ol-0-0-8271){ref-type="fig"}, a total of 78 and 17 transcription factors were identified for MALAT1 and HOTAIR, respectively. As presented in [Fig. 5](#f5-ol-0-0-8271){ref-type="fig"}, a total of 13 and 59 transcription factors were identified for hsa-miR-1 and has-miR-20a-5p, respectively. A total of 7 overlaps were identified between hsa-miR-1 and has-miR-20a-5p ([Fig. 5](#f5-ol-0-0-8271){ref-type="fig"}).

### Identification of HCC-associated transcription factors

HCC-associated transcription factors were identified using PubMed. The results demonstrated that there were nine lncRNA transcription factors associated with HCC: Signal transducer and activator of transcription 1 (STAT1), hepatocyte nuclear factor 4α (HNF4A), octamer-binding transcription factor 4 (Oct-4), Nanog homeobox (NANOG), caudal type homeobox 2 (CDX2), DEAD-box helicase 5 (p68), brahma-related gene 1 (Brg1), MYC-associated factor X (Max) and MYC proto-oncogene, BHLH transcription factor (c-Myc) ([@b29-ol-0-0-8271]--[@b36-ol-0-0-8271]). Additionally, CDX2, erythroblast transformation-specific-related gene (ERG), forkhead box protein A1 (FOXA1), HNF4A, c-Jun and NANOG were identified as the transcription factors for hsa-miR-1 and hsa-miR-20a-5p ([@b30-ol-0-0-8271]--[@b32-ol-0-0-8271],[@b37-ol-0-0-8271]--[@b39-ol-0-0-8271]). CDX2, HNF4A and NANOG were identified to be common between the target lncRNAs and miRNAs ([Fig. 6](#f6-ol-0-0-8271){ref-type="fig"}).

### Identification of target genes for hsa-miR-1 and hsa-miR-20a-5p

The target genes for hsa-miR-1 and hsa-miR-20a-5p were predicted using the miRWalk database. A total of 879 and 101 target genes were identified for hsa-miR-1 and has-miR-20a-5p, respectively. A total of 32 overlaps were identified between these target miRNAs ([Fig. 7](#f7-ol-0-0-8271){ref-type="fig"}).

### Identification of the HCC-associated target genes for hsa-miR-1 and hsa-miR-20a-5p

The OncoDB.HCC database was used for the identification of the HCC-associated target genes for hsa-miR-1 and hsa-miR-20a-5p. As presented in [Table II](#tII-ol-0-0-8271){ref-type="table"}, among the 32 target genes, 11 of them were involved in the progression of HCC. As miRNAs are single-stranded RNA molecules that bind to targets in a base pair-mediated manner, resulting in the degradation or inhibition of the expression and function of target genes, the expression of the target genes were inverse to that of the miRNAs ([@b40-ol-0-0-8271]), Then, seven target genes \[cyclin D1, E2F transcription factor 1 (E2F1), epithelial growth factor receptor (EGFR), MYC, MET proto-oncogene, receptor tyrosine kinase (MET), nitric oxide synthase 2A (NOS2A) and vascular endothelial growth factor (VEGF)\] with increased expression in HCC were selected for the further analysis.

### GO and KEGG pathway enrichment analysis of the target genes

GO and KEGG pathway enrichment analysis of identified target genes was performed using DAVID. GO analysis revealed that six genes were involved in cellular functions such as cell growth, cycle and mitosis ([Table III](#tIII-ol-0-0-8271){ref-type="table"}). Additionally, KEGG analysis revealed that six genes were involved in the cell cycle and focal adhesion, and in disease progression ([Table IV](#tIV-ol-0-0-8271){ref-type="table"}). NOS2A was excluded from further analysis.

### Prediction of the transcription factors for the HCC-associated miRNAs

The transcription factors for the HCC-associated miRNAs were predicted using ConSite ([Fig. 8](#f8-ol-0-0-8271){ref-type="fig"}). The results demonstrated that snail family transcriptional repressor 1 (Snail) was a common transcription factor for the six target genes and was involved in the progression of HCC ([Table V](#tV-ol-0-0-8271){ref-type="table"}) ([@b41-ol-0-0-8271]).

### Functional regulatory network of lncRNA in HCC

[Fig. 9](#f9-ol-0-0-8271){ref-type="fig"} presents the proposed regulatory network of lncRNAs in HCC.

Discussion
==========

Following advances in proteomics and genomics, the function of numerous human ncRNAs has been investigated. On the basis of their length and biological function, ncRNAs can be divided into miRNAs, small nucleolar RNA, small nuclear RNAs, piwi-interacting RNAs, natural antisense transcripts, ribosomal RNAs, transfer RNAs and lncRNAs ([@b42-ol-0-0-8271]). A total of 270 lncRNAs have been documented in the lncRNAdb database ([@b20-ol-0-0-8271]). Several studies have demonstrated that lncRNAs may serve notable functions in cell physiological activities, in the development of various types of tumor and in epigenetics, transcriptional and post-transcriptional mechanisms ([@b42-ol-0-0-8271]--[@b46-ol-0-0-8271]).

Bioinformatics is a powerful tool for genomic research that facilitates the identification of candidate genes and nucleotide sequences, and predicts the biological functions and regulatory pathways of the target genes. At present, research into lncRNAs is limited. In the present study, HCC-associated lncRNAs (HOTAIR, MALAT1 and HULC) were identified using lncRNA disease database. According to data from the UCSC Genome Browser and lncRNA disease database, HOTAIR was located on human chromosome 12 (12649 bp) and exhibited a low expression in the liver, but increased expression in HCC ([@b47-ol-0-0-8271]). HOTAIR may inhibit the expression of interferon-γ and cell cycle-associated genes, thus promoting cellular invasion in HCC. Knockout of HOTAIR significantly decreased cellular proliferation and promoted apoptosis in HCC ([@b48-ol-0-0-8271],[@b49-ol-0-0-8271]). The 3-year recurrence-free survival rate for patients with HCC that exhibited low expression of HOTAIR was significant increased compared with that in patients with high expression of lncRNA following liver transplantation. Therefore, HOTAIR may be used as an independent indicator for tumor recurrence following liver transplantation ([@b47-ol-0-0-8271]). The results of the present study demonstrated that MALAT1 was located on human chromosome 11q13 (8708 bp), with a length of 870 bp. MALAT1 was identified in various tissues and exhibited increased expression levels in HCC ([@b50-ol-0-0-8271]). One previous study ([@b51-ol-0-0-8271]) demonstrated that MALAT1 may promote cellular proliferation in HCC, and patients with HCC with increased expression of MALAT1 exhibited an increased risk of tumor recurrence. Therefore, MALAT1 may be used for the prediction of HCC recurrence. MALAT1 may regulate the migration of HCC cells ([@b52-ol-0-0-8271]). The results of the present study demonstrated that HULC was located on human chromosome 6p24.3. The expression of HULC was increased in the liver but low in HCC tissues ([@b53-ol-0-0-8271]).

lncRNAs may interact with miRNAs ([@b54-ol-0-0-8271]). The results of previous studies have indicated that the interaction of lncRNAs and miRNAs serve a notable function in the progression of cancer ([@b55-ol-0-0-8271]--[@b57-ol-0-0-8271]). In the present study, starBase2.0 was used to predict the miRNAs that were associated with lncRNAs (HOTAIR, MALAT1 and HULC). However, no miRNA was identified to interact with HULC, so further analyses were performed on HOTAIR and MALAT1 only. A total of 11 overlaps were identified between HOTAIR and MALAT1, 9 of which were HCC-associated miRNAs according to the HMDD database. hsa-miR-1 and hsa-miR20a-5p were identified to be downregulated in HCC and selected for further analysis.

ChIPBase was used to predict the transcription factors for lncRNAs (MALAT1 and HOTAIR) and miRNAs (hsa-miR-1 and hsa-miR-20a-5p). The results demonstrated that 9 transcription factors for lncRNAs (STAT1, HNF4A, Oct-4, NANOG, CDX2, p68, Brg1, Max and c-Myc) were associated with HCC. Additionally, CDX2, ERG, FOXA1, HNF4A, c-Jun and NANOG were identified to associate with the target miRNAs and were associated with the progression of HCC. Among them, CDX2, HNF4A and NANOG were identified as the transcription factors in common for these lncRNAs and miRNAs.

In the present study, a total of 32 target genes were identified for hsa-miR-1 and hsa-miR-20a-3p using miRWalk. Among them, 11 genes were involved in the development of HCC, according to the OncoDB.HCC database. A total of seven target genes with increased expression in HCC (cyclin D1, E2F1, EGFR, MYC, MET, NOS2A, VEGFA) were selected for the further analysis. Additionally, GO and KEGG enrichment analysis was performed on the seven HCC-associated miRNA target genes using DAVID. The results demonstrated that six genes were involved in various cellular functions, including cell growth, cell cycle progression and mitosis. KEGG analysis revealed that six genes were involved in the cell cycle, focal adhesion and disease progression

Snail was predicted to be the transcription factor in common among the six target genes and was involved in the progression of HCC according to data from ConSite. A previous study demonstrated that upregulation of Snail may promote the proliferation and invasion of HCC cells ([@b58-ol-0-0-8271]). Therefore, in the present study a complete regulatory network of lncRNAs in HCC was proposed, whereby each one of the participants was either directly or indirectly associated and whose deregulation may result in HCC progression. Nevertheless, further research is required to confirm these regulatory associations.

In the present study the function and regulatory network of HCC-associated lncRNAs (HOTAIR and MALAT1) was predicted using bioinformatics analysis to understand the molecular mechanisms underlying the progression of HCC.
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###### 

Hepatocellular carcinoma-associated lncRNAs obtained from the lncRNA disease database.

  lncRNA     Dysfunction type   Chromosome   Genbank
  ---------- ------------------ ------------ --------------
  H19        Expression         11           NR_002196.1
             Expression         11           NR_002196.48
             N/A                11           NR_002196.17
             Expression         11           NR_002196.1
             Regulation         11           NR_002196.1
  HEIH       Expression         5            NR_045680.1
  HOTAIR     Expression         12           NR_047517.1
             Expression         12           NR_047517.10
             Expression         12           NR_047517.13
             Expression         12           NR_047517.3
             Expression         12           NR_047517.1
             Expression         12           NR_047517.15
             Regulation         12           NR_047517.1
  HOTTIP     Expression         7            NR_037843.3
             Expression         7            NR_037843.3
             Expression         7            NR_037843.2
  HULC       Expression         6            NR_004855.2
             Regulation         6            NR_004855.2
             Regulation         6            NR_004855.2
             Expression         6            NR_004855.3
             Expression         6            NR_004855.4
             Expression         6            NR_004855.6
             Expression         6            NR_004855.2
             Regulation         6            NR_004855.2
  IGF2-AS    N/A                11           NR_028044.1
  KCNQ1OT1   Mutation           11           NR_002728.3
  MALAT1     Expression         11           NR_002819.2
             Expression         11           NR_002819.2
             Expression         11           NR_002819.7
             Expression         11           NR_002819.12
             Expression         11           NR_002819.17
             Mutation           11           NR_002819.5
             Expression         11           NR_002819.2
  MEG3       Expression         14           NR_002766.2
             Expression         14           NR_002766.15
             Regulation         14           NR_002766.2
  MINA       Expression         3            XR_241516.2
  MIR7-3HG   Expression         19           NR_027148.1
  NPTN-IT1   Expression         15           AK055007.1
             Expression         15           AK055007.1

HCC, hepatocellular carcinoma; lncRNA, long non-coding RNA; HEIH, hepatocellular carcinoma upregulated EZH2-associated long non-coding RNA HOTAIR, HOX transcript antisense RNA; HOTTIP, HOXA distal transcript antisense RNA; HULC, highly upregulated in liver cancer; IGF2-AS, insulin-like growth factor 2-antisense RNA; KCNQ1OT1, KCNQ1 overlapping transcript 1; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MEG3, maternally expressed 3; MINA, MYC induced nuclear antigen; MIR7-3HG, MIR7-3 host gene; NPTN-IT1, NPTN intronic transcript 1; N/A, not available.

###### 

HCC-associated miRNA target genes obtained from the OncoDB.HCC database.

  Gene     Description                                                                                                                                                        Evidence
  -------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------
  CCND1    G1/S-specific cyclin-D1 (PRAD1 oncogene)                                                                                                                           Arrays: C.R.01a, PNAS01, MBC 02
           (BCL-1 oncogene). \[Source: Uniprot/SWISSPROT; Acc: P24385\]                                                                                                       Experiments: upregulated (RT-PCR, IHC and western blotting)
  E2F1     Transcription factor E2F1 (E2F-1) (Retinoblastoma-binding protein 3) (RBBP-3) (PRB-binding protein E2F-1) (PBR3) (Retinoblastoma-associated protein 1) (RBAP-1).   Experiments: upregulated (RT-PCR)
           \[Source: Uniprot/SWISSPROT; Acc: Q01094\]                                                                                                                         
  EGFR     Epidermal growth factor receptor precursor (EC 2.7.10.1)                                                                                                           Experiments: upregulated (IHC)
           (Receptor tyrosine-protein kinase ErbB-1). \[Source: Uniprot/SWISSPROT; Acc: P00533\]                                                                              
  MYC      Myc proto-oncogene protein (c-Myc) (Transcription factor p64). \[Source: Uniprot/SWISSPROT; Acc: P01106\]                                                          Arrays: PNAS01, Onc. 02, MBC 02 Experiments: upregulated (RT-PCR and IHC)
  NOS2A    Nitric oxide synthase, inducible (EC 1.14.13.39) (NOS type II) (Inducible NO synthase) (Inducible NOS) (iNOS) (Hepatocyte NOS) (HEP-NOS).                          Experiments: upregulated (RT-PCR)
           \[Source: Uniprot/SWISSPROT; Acc: P35228\]                                                                                                                         
  VEGFA    Vascular endothelial growth factor A precursor (VEGF-A) (Vascular permeability factor) (VPF). \[Source: Uniprot/SWISSPROT; Acc: P15692\]                           Experiments: upregulated (Northern blotting and IHC)
  MET      Hepatocyte growth factor receptor precursor (EC 2.7.10.1)                                                                                                          Experiments: upregulated (RT-PCR and mutation)
           (HGF receptor) (Scatter factor receptor) (SF receptor) (HGF/SF receptor) (Met proto-oncogene tyrosine kinase) (c-Met).                                             
           \[Source: Uniprot/SWISSPROT; Acc: P08581\]                                                                                                                         
  CDKN1A   Cyclin-dependent kinase inhibitor 1 (p21) (CDK-interacting protein 1) (Melanoma differentiation-associated protein 6)                                              Arrays: Gast01, Onc.02, J.H.03 Experiments: downregulated (IHC and RT-PCR)
           (MDA-6). \[Source: Uniprot/SWISSPROT; Acc: P38936\]                                                                                                                
  NPM1     Nucleophosmin (NPM) (Nucleolar phosphoprotein B23)                                                                                                                 Arrays: PNAS01, MBC02, CCR03, Prot05a, Prot05c
           (Numatrin) (Nucleolar protein NO38). \[Source: Uniprot/SWISSPROT; Acc: P06748\]                                                                                    
  THBS1    Thrombospondin-1 precursor. \[Source: Uniprot/SWISSPROT; Acc: P07996\]                                                                                             Experiments: downregulated (qPCR)
  TP53     Cellular tumor antigen p53 (Tumor suppressor p53) (Phosphoprotein p53) (Antigen NY-CO-13).                                                                         Experiments: other (IHC, western blotting, mutation and methylation)
           \[Source: Uniprot/SWISSPROT; Acc: P04637\]                                                                                                                         

HCC, hepatocellular carcinoma; miR, microRNA; RT-PCR, reverse transcription-polymerase chain reaction; IHC, immunohistochemistry; qPCR, quantified polymerase chain reaction.

###### 

GO enrichment analysis for the seven HCC-associated miRNA target genes.

  GO ID        Term                                                   Genes                         Percentage^[a](#tfn3-ol-0-0-8271){ref-type="table-fn"}^   P-value       Benjamini^[b](#tfn4-ol-0-0-8271){ref-type="table-fn"}^
  ------------ ------------------------------------------------------ ----------------------------- --------------------------------------------------------- ------------- --------------------------------------------------------
  GO:0008283   Cell proliferation                                     E2F1, EGFR, MET, MYC, VEGFA   83.3                                                      5.20×10^−6^   2.40×10^−3^
  GO:0051726   Regulation of cell cycle                               E2F1, CCND1, EGFR, MYC        66.7                                                      1.40×10^−4^   3.20×10^−2^
  GO:0008284   Positive regulation of cell proliferation              CCND1, EGFR, MYC, VEFA        66.7                                                      2.70×10^−4^   4.10×10^−2^
  GO:0044093   Positive regulation of molecular function              CCND1, EGFR, MET, MYC         66.7                                                      7.60×10^−4^   4.20×10^−2^
  GO:0009891   Positive regulation of biosynthetic process            E2F1, EGFR, MYC, VEGFA        66.7                                                      1.20×10^−3^   4.30×10^−2^
  GO:0022402   Cell cycle process                                     E2F1, CCND1, EGFR, MYC        66.7                                                      6.80×10^−4^   4.40×10^−2^
  GO:0051325   Interphase                                             E2F1, CCND1, EGFR             50                                                        6.00×10^−4^   4.50×10^−2^
  GO:0007346   Regulation of mitotic cell cycle                       CCND1, EGFR, MYC              50                                                        1.20×10^−3^   4.60×10^−2^
  GO:0031328   Positive regulation of cellular biosynthetic process   E2F1, EGFR, MYC, VEGFA        66.7                                                      1.20×10^−3^   4.90×10^−2^

Percentage of target genes from current functional annotation that are total target genes

Benjamini-corrected P-value. HCC, hepatocellular carcinoma; miR, microRNA; GO, gene ontology.

###### 

KEGG pathway enrichment analysis for the seven HCC-associated miRNA target genes.

  KEGG ID    Term                         Genes                                Percentage^[a](#tfn5-ol-0-0-8271){ref-type="table-fn"}^   P-value       Benjamini^[b](#tfn6-ol-0-0-8271){ref-type="table-fn"}^
  ---------- ---------------------------- ------------------------------------ --------------------------------------------------------- ------------- --------------------------------------------------------
  hsa05219   Bladder cancer               E2F1, CCND1, EGFR, MYC, VEGFA        83.3                                                      2.00×10^−8^   7.00×10^−7^
  hsa05200   Pathways in cancer           E2F1, CCND1, EGFR, MET, MYC, VEGFA   100                                                       1.10×10^−6^   1.90×10^−5^
  hsa05218   Melanoma                     E2F1, CCND1, EGFR, MET               66.7                                                      2.60×10^−5^   3.00×10^−4^
  hsa05212   Pancreatic cancer            E2F1, CCND1, EGFR, VEGFA             66.7                                                      2.70×10^−5^   2.30×10^−4^
  hsa05210   Colorectal cancer            CCND1, EGFR, MET, MYC                66.7                                                      4.20×10^−5^   3.00×10^−4^
  hsa04510   Focal adhesion               CCND1, EGFR, MET, VEGFA              66.7                                                      5.70×10^−4^   3.30×10^−3^
  hsa05213   Endometrial cancer           CCND1, EGFR, MYC                     50                                                        1.00×10^−3^   5.00×10^−3^
  hsa05223   Non-small cell lung cancer   E2F1, CCND1, EGFR                    50                                                        1.10×10^−3^   4.70×10^−3^
  hsa05214   Glioma                       E2F1, CCND1, EGFR                    50                                                        1.50×10^−3^   5.70×10^−3^
  hsa05220   Chronic myeloid leukemia     E2F1, CCND1, MYC                     50                                                        2.10×10^−3^   7.30×10^−3^
  hsa05222   Small cell lung cancer       E2F1, CCND1, MYC                     50                                                        2.60×10^−3^   8.30×10^−3^
  hsa05212   Prostate cancer              E2F1, CCND1, EGFR                    50                                                        2.90×10^−3^   8.50×10^−3^
  hsa04110   Cell cycle                   E2F1, CCND1, MYC                     50                                                        5.70×10^−3^   1.50×10^−2^

Percentage of target genes from current functional annotation that are total target genes

Benjamini-corrected P-value. HCC, hepatocellular carcinoma; miR, microRNA; KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Prediction of the overlapping transcription factors for the six target genes using ConSite.

  Transcription factor   Sequence     From (position)   To (position)   Score
  ---------------------- ------------ ----------------- --------------- --------
  Hunchback              TTTTTTATGC   6,433             6,442           12.824
  AML-1                  TTTGTGGTT    2,631             2,639           12.626
  c-REL                  GGGGTTTTCC   8,856             8,865           12.159
  E74A                   CCGGAAG      6,379             6,385           10.755
  Snail                  CAGGTG       2,151             2,156           10.744
  Thing1-E47             GGTCTGGCTT   1,529             1,538           12.164

TF, transcription factor; AML-1, acute myeloid leukemia protein-1; c-REL, proto-oncogene c-Rel; E74A, ETS transcription factor E74A.

[^1]: Contributed equally
